Literature DB >> 14716310

TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Eicke Latz1, Annett Schoenemeyer, Alberto Visintin, Katherine A Fitzgerald, Brian G Monks, Cathrine F Knetter, Egil Lien, Nadra J Nilsen, Terje Espevik, Douglas T Golenbock.   

Abstract

Microbial DNA sequences containing unmethylated CpG dinucleotides activate Toll-like receptor 9 (TLR9). We have found that TLR9 is localized to the endoplasmic reticulum (ER) of dendritic cells (DCs) and macrophages. Because there is no precedent for immune receptor signaling in the ER, we investigated how TLR9 is activated. We show that CpG DNA binds directly to TLR9 in ligand-binding studies. CpG DNA moves into early endosomes and is subsequently transported to a tubular lysosomal compartment. Concurrent with the movement of CpG DNA in cells, TLR9 redistributes from the ER to CpG DNA-containing structures, which also accumulate MyD88. Our data indicate a previously unknown mechanism of cellular activation involving the recruitment of TLR9 from the ER to sites of CpG DNA uptake, where signal transduction is initiated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716310     DOI: 10.1038/ni1028

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  456 in total

1.  Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation.

Authors:  Maria L Mouchess; Nicholas Arpaia; Gianne Souza; Roman Barbalat; Sarah E Ewald; Laura Lau; Gregory M Barton
Journal:  Immunity       Date:  2011-11-10       Impact factor: 31.745

2.  TLR9 is localized in the endoplasmic reticulum prior to stimulation.

Authors:  Cynthia A Leifer; Margaret N Kennedy; Alessandra Mazzoni; ChangWoo Lee; Michael J Kruhlak; David M Segal
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

3.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

4.  Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses.

Authors:  Maroof Hasan; Catarina Ruksznis; Yan Wang; Cynthia Anne Leifer
Journal:  J Immunol       Date:  2011-11-02       Impact factor: 5.422

5.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.

Authors:  Chasity D Andrews; Myung-Sook Huh; Kathryn Patton; Debbie Higgins; Gary Van Nest; Gary Ott; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

Review 6.  Important aspects of Toll-like receptors, ligands and their signaling pathways.

Authors:  Z L Chang
Journal:  Inflamm Res       Date:  2010-07-01       Impact factor: 4.575

7.  UNC93B1 is essential for the plasma membrane localization and signaling of Toll-like receptor 5.

Authors:  Ji-Won Huh; Takuma Shibata; Misun Hwang; Eun-Hye Kwon; Min Seong Jang; Ryutaro Fukui; Atsuo Kanno; Da-Jung Jung; Myoung Ho Jang; Kensuke Miyake; You-Me Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

Review 8.  Traditional biochemical assays for studying toll-like receptor 9.

Authors:  Cynthia A Leifer; William A Rose; Fernando Botelho
Journal:  J Immunoassay Immunochem       Date:  2013

Review 9.  The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.

Authors:  Lei Wu; Lili Yang
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

10.  Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection.

Authors:  Heather Donaghy; Lidija Bosnjak; Andrew N Harman; Valerie Marsden; Stephen K Tyring; Tze-Chiang Meng; Anthony L Cunningham
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.